A DEA administrative law judge has denied MedPharm's motion to participate in the December 2 marijuana rescheduling hearing, deferring to DEA Administrator Anne Milgram's authority. MedPharm, a ...
Pennington pointed out in his motion that the DEA approved as witnesses officials from Nebraska, which opposes ...
A researcher has filed a lawsuit against the Drug Enforcement Administration, accusing the agency of multiple legal ...
The DEA could allow more participants to testify at upcoming hearings concerning marijuana rescheduling in addition to the ...
DEA and anti-cannabis group must respond to allegations of unlawful talks by November 25. Legal tensions rise ahead of ...
By Terry Hacienda, The Fresh Toast It has been clear the DEA It has been clear Anne Milgram, the head of the D ...
The group sees Schedule III as "inadequate" for veterans' needs. But the DEA excluded it from the witness list, and a judge ...
The motion, which asks the DOJ to take over moving cannabis down the list, argues the DEA has "stacked the deck" against ...
The cannabis industry is concerned about the direction of regulations – and the DEA is still against the plant.
Speaking of medical product, the one bright spot in the 2024 election is that, of the two votes that passed in Nebraska, one ...
Schedule III drugs, as defined by the DEA, are "drugs with a moderate to low potential for physical and psychological ...
Filing asserts that the DEA failed to maintain a complete record and ensure fairness and transparency – – Filing also asserts DEA is compromised and should be barred from participation in these ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback